EICHOR
● Completed
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis · Sponsor: Eli Lilly and Company
About this study
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (119)
| Arizona Research Clinic PLLC | Chandler, Arizona, United States | — |
| Arizona Arthritis & Rheumatology Associates, P. C. | Mesa, Arizona, United States | — |
| Arizona Arthritis & Rheumatology Research | Paradise Valley, Arizona, United States | — |
| Sun Valley Arthritis Center, LTD | Peoria, Arizona, United States | — |
| Arizona Arthritis & Rheumatology Associates | Phoenix, Arizona, United States | — |
| Arthritis and Rheumatism Associates | Jonesboro, Arkansas, United States | — |
| Providence St. Joseph's Medical Center | Burbank, California, United States | — |
| Hope Clinical Research, Inc. | Canoga Park, California, United States | — |
| Medvin Clinical Research - Covina | Covina, California, United States | — |
| TriWest Research Associates LLC | El Cajon, California, United States | — |
| Newport Huntington Med Grp | Huntington Beach, California, United States | — |
| BioSolutions Clinical Research Center | La Mesa, California, United States | — |
+ 107 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.